Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Common Equity (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Common Equity data on record, last reported at $992.1 million in Q4 2025.

  • For Q4 2025, Common Equity fell 25.11% year-over-year to $992.1 million; the TTM value through Dec 2025 reached $992.1 million, down 25.11%, while the annual FY2025 figure was $992.1 million, 25.11% down from the prior year.
  • Common Equity reached $992.1 million in Q4 2025 per CRNX's latest filing, down from $1.1 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.3 billion in Q4 2024 and bottomed at $149.5 million in Q1 2021.
  • Average Common Equity over 5 years is $610.4 million, with a median of $462.6 million recorded in 2022.
  • Peak YoY movement for Common Equity: plummeted 34.19% in 2023, then soared 226.92% in 2024.
  • A 5-year view of Common Equity shows it stood at $331.9 million in 2021, then dropped by 4.7% to $316.3 million in 2022, then soared by 70.43% to $539.1 million in 2023, then surged by 145.74% to $1.3 billion in 2024, then dropped by 25.11% to $992.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $992.1 million in Q4 2025, $1.1 billion in Q3 2025, and $1.2 billion in Q2 2025.